Feasibility of Adjunctive Nutritional Therapy for Patients with Crohn’s Disease Starting New Immunologic Therapy
Authors: Levi Teigen1, Lulu Chen1, Sharon Lopez1, Andrew Sommer1, Byron Vaughn1
Research Presented as a Poster at the 2026 Annual Scientific Conference for The American Society for Nutrition (ASN)
Population and Design
Prospective, randomized, controlled, open-label, pilot study of 20 adults starting immunologic therapy for a Crohn’s Disease flare.
Participants received either a standardized IBD anti-inflammatory diet instruction alone or the same diet combined with an oral nutrition supplement—provided by an organic pea peptide formula—for 8 weeks.
Outcomes Measured
Dietary intake, body composition, and fecal microbiome.
Results
Protein intake improved by 29 g/day and 12 g/day at weeks 2 and 4 for patients consuming the organic pea peptide formula but was unchanged in patients receiving diet instruction alone.
Calorie intake improved by 164 kcal/day and 105 kcal/day at weeks 2 and 4 for patients consuming the organic pea peptide formula but was unchanged in the control group.
Non-hydrated lean tissue (NHLT) improved by 2.1 kg starting at week 4 in the organic pea peptide formula group. For the control group, NHLT improved starting at week 8 by 3.1 kg.
Fat-free mass percent (FFM%) improved by 2.2 % starting at week 4 in patients consuming organic pea peptide formula. For the control group, FFM% improved starting at week 8 by 2.8 %.
Read Full-Text Abstract from ASN's NUTRITION2026 Conference
Affiliations:
1. University of Minnesota, MN, United States
Citation:
Teigen L et al., 2026; Curr Dev Nutr, 10(2026): 108003
Loading form...
We'll have your form in just a moment